Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsDowngradesPrice Target
Truist Securities analyst Danielle Brill downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $315 to $225.
Truist Securities analyst Danielle Brill downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $315 to $225.